Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246582 · ClinicalTrials.gov registry record · NA
Adult Accuracy Study of the Enlite 3 Glucose Sensor
A NA study, sponsored by Medtronic MiniMed.
- Completed
- Registry status
- NA
- Development phase
- 118
- Enrollment target
NCT02246582: Completed NA study, sponsored by Medtronic MiniMed.
NCT02246582 is a NA study that has completed, run by Medtronic MiniMed. The registered enrollment target is 118 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02246582, a NA study, has completed, sponsored by Medtronic MiniMed.
- COMPLETED
- Registry status
- NA
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the performance of the Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen and used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years with type 1 or type 2 diabetes.
Primary Outcome
Enlite 3 Sensor accuracy using two real time devices: 1) 640G Pump and 2) Guardian Mobile with the minimum calibration requirements (every 12 hours after the second calibration) will be evaluated. Enlite 3 Sensor values will be compared to YSI plasma glucose values, which is considered as the gold standard, during the frequent sample testing days (Days 1, 3 and 7). MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) \* 100). Note that r
Interventions
- DEVICE Enlite 3
- DEVICE Guardian Mobile App
- DEVICE 640G Insulin Pump
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-08 |
| Phase | NA |
What the finished NCT02246582 record still lists
NCT02246582 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Enlite 3 is the first listed.
NCT02246582 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02246582 about?
NCT02246582 is a clinical study titled "Adult Accuracy Study of the Enlite 3 Glucose Sensor". The purpose of this study is to demonstrate the performance of the Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen and used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years with type 1 or type 2 diabetes.
What is the current status of trial NCT02246582?
This trial is currently completed. It is a NA study. The enrollment target is 118 participants. The study started on 2014-09. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02246582?
The interventions under investigation include: Enlite 3 (DEVICE), Guardian Mobile App (DEVICE), 640G Insulin Pump (DEVICE).
Who is sponsoring clinical trial NCT02246582?
This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02246582's enrollment target sits among peer trials
118 803rd of 2000 higher than 1,194 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia